Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 11/20 | 0.37 |
| ▸ | NPR1 | P16066 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703868 | 0.89 | NRP1 (0.49) | NRP1NPR1 | |
| SCHEMBL13552607 | 0.83 | NRP1 (0.42) | NRP1NPR1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13554616 | 0.80 | NRP1 (0.49) | NRP1NPR1 | |
| SCHEMBL13552546 | 0.79 | NRP1 (0.38) | NRP1NPR1NOD2 | |
| SCHEMBL13552572 | 0.78 | NRP1 (0.56) | NRP1NPR1SLC10A6 | |
| SCHEMBL13552613 | 0.76 | NRP1 (0.35) | NRP1NPR1ALDH1A1SMN1; SMN2BMP1 | |
| SCHEMBL13552599 | 0.75 | NRP1 (0.47) | NRP1NPR1 | |
| SCHEMBL3692787 | 0.74 | NRP1 (0.53) | NRP1NPR1 | |
| SCHEMBL4569861 | 0.73 | NRP1 (0.50) | NRP1NPR1 | |
| SCHEMBL13552534 | 0.73 | NRP1 (0.53) | NRP1NPR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NRP1 145/4885NPR1 2/4885ALDH1A1 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.